+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 60 Pages
  • July 2024
  • GlobalData
  • ID: 4284797
Travere Therapeutics Inc (TVTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, and commercializes drugs for the treatment of rare diseases. The company’s products include thiola, chenodal, and cholbam. It develops drugs for therapies for people living with liver, rare kidney and metabolic diseases. Travere Therapeutics' marketed product Filspari (sparsentan), is developed to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Its pipeline products include sparsentan which is being developed for the treatment of focal segmental glomerulosclerosis and Pegtibatinase (TVT-058) being developed for the treatment of classical homocystinuria (HCU). The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.

Travere Therapeutics Inc Key Recent Developments

  • May 06, 2024: Travere Therapeutics Reports First Quarter 2024 Financial Results
  • Mar 14, 2024: IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
  • Feb 15, 2024: Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
  • Nov 07, 2023: Travere Therapeutics Reports Third Quarter 2023 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Travere Therapeutics Inc - Key Facts
  • Travere Therapeutics Inc - Key Employees
  • Travere Therapeutics Inc - Key Employee Biographies
  • Travere Therapeutics Inc - Major Products and Services
  • Travere Therapeutics Inc - History
  • Travere Therapeutics Inc - Company Statement
  • Travere Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Travere Therapeutics Inc - Business Description
  • Other Break-up: License and Collaboration Revenue
  • Performance
  • Other Break-up: Net Product Sales
  • Performance
  • R&D Overview
  • Travere Therapeutics Inc - Corporate Strategy
  • Travere Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Travere Therapeutics Inc - Strengths
  • Travere Therapeutics Inc - Weaknesses
  • Travere Therapeutics Inc - Opportunities
  • Travere Therapeutics Inc - Threats
  • Travere Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Travere Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 06, 2024: Travere Therapeutics Reports First Quarter 2024 Financial Results
  • Mar 14, 2024: IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
  • Feb 15, 2024: Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
  • Nov 07, 2023: Travere Therapeutics Reports Third Quarter 2023 Financial Results
  • Oct 24, 2023: Travere Therapeutics to Report Third Quarter 2023 Financial Results
  • Aug 03, 2023: Travere Therapeutics Reports Second Quarter 2023 Financial Results
  • May 04, 2023: Travere Therapeutics reports first quarter 2023 financial results
  • Feb 23, 2023: Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
  • Feb 16, 2023: Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
  • Jan 09, 2023: Travere Therapeutics Provides Corporate Update and 2023 Outlook
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Travere Therapeutics Inc, Key Facts
  • Travere Therapeutics Inc, Key Employees
  • Travere Therapeutics Inc, Key Employee Biographies
  • Travere Therapeutics Inc, Major Products and Services
  • Travere Therapeutics Inc, History
  • Travere Therapeutics Inc, Subsidiaries
  • Travere Therapeutics Inc, Key Competitors
  • Travere Therapeutics Inc, Ratios based on current share price
  • Travere Therapeutics Inc, Annual Ratios
  • Travere Therapeutics Inc, Interim Ratios
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Travere Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Travere Therapeutics Inc, Performance Chart (2019 - 2023)
  • Travere Therapeutics Inc, Ratio Charts
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Travere Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pharmesis International Ltd
  • Eledon Pharmaceuticals Inc
  • Alpine Immune Sciences Inc
  • Acelyrin Inc
  • Stada Arzneimittel AG
  • SciClone Pharmaceuticals Holdings Ltd
  • Omeros Corp
  • MorphoSys AG
  • Ginkgo Bioworks Holdings Inc
  • DiaMedica Therapeutics Inc
  • Voyager Therapeutics Inc
  • Takeda Pharmaceuticals USA Inc
  • Novartis AG
  • Leadiant Biosciences Inc
  • BioCryst Pharmaceuticals Inc
  • AstraZeneca Plc
  • Calliditas Therapeutics US Inc
  • Viatris Pharmaceuticals Japan Inc
  • Teva Pharmaceuticals USA Inc
  • Par Pharmaceutical Inc
  • AbbVie Inc
  • Vera Therapeutics Inc
  • Torrent Pharmaceuticals Ltd
  • Everest Medicines US Ltd
  • Arrowhead Pharmaceuticals Inc
  • Synlogic Inc
  • Roche Holding AG
  • Otsuka Corp
  • Jiangsu Hengrui Medicine Co Ltd
  • Ionis Pharmaceuticals Inc
  • CoA Therapeutics Inc
  • Intercept Pharmaceuticals Inc
  • Human Immunology Biosciences Inc
  • Falk Pharma Gmbh
  • Boehringer Ingelheim International GmbH
  • Advicenne SA